Drug
Surabgene Lomparvovec
Surabgene Lomparvovec: highest development phase Phase 3, developed by AbbVie. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AbbVie
Trials
| Drug | Phase | Indication |
|---|---|---|
| Surabgene Lomparvovec (ABBV-RGX-314) NCT07007065 | Phase 3 | Neovascular Age-related Macular Degeneration |
Latest
No recent events.
Follow Surabgene Lomparvovec on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.